Oxalo Therapeutics was founded with the core mission of developing first-in-class therapeutics to treat and prevent diseases caused by hyperoxaluria and hyperoxalemia. The company focuses on preserving long-term kidney health by addressing rare renal diseases and preventing recurrent kidney stones, starting with primary hyperoxaluria, a monogenic autosomal recessive liver disease that results in excessive endogenous oxalate. Oxalo Therapeutics' innovative approach aims to provide effective solutions for these debilitating conditions.

Notable affiliated people include experts in nephrology and biotechnology, though specific names are not provided. The company has attracted attention from investors interested in groundbreaking medical treatments. Key achievements include the development of promising drug candidates targeting hyperoxaluria, positioning Oxalo Therapeutics as a leader in the niche market of renal disease therapeutics. The overall impact of Oxalo Therapeutics lies in its potential to significantly improve the quality of life for patients suffering from rare kidney disorders.